XML 38 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Investments in Joint Ventures and Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]  
Summary of carrying amounts of assets and fair value of liabilities included in Condensed Consolidated Balance Sheet and maximum loss exposure in VIE
The following table summarizes the carrying amounts of the assets and the fair value of the liabilities included in the Company’s condensed consolidated balance sheet and the maximum loss exposure related to the Company’s interest in its unconsolidated VIE (the Solazyme Bunge JV) as of September 30, 2015 (in thousands):
 
Assets
 
Liabilities
 
 
VIE
Accounts
Receivable
 
Unbilled
Revenues
 
Investment in
Unconsolidated
Joint Venture
 
Loan
Guarantee
 
Maximum
Exposure
to Loss (1)
Solazyme Bunge JV
$
12

 
$

 
$
36,185

 
$

 
$
45,239

 
(1)
Includes maximum exposure to loss attributable to the Company’s bank guarantee required to be provided for the Solazyme Bunge JV of R$35.4 million (approximately $8.6 million based on the exchange rate at September 30, 2015) and non-cancelable purchase obligations of R$1.7 million (approximately $0.4 million based on the exchange rate at September 30, 2015).
Summarized financial information on Solazyme Bunge JV's Balance Sheets and Income Statements
Summarized information on the Solazyme Bunge JV’s balance sheets and income statements as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014, respectively, was as follows (in thousands):
 
September 30,
2015
 
December 31,
2014
Current assets
$
9,599

 
$
4,339

Noncurrent assets
107,714

 
161,751

Total assets
$
117,313

 
$
166,090

Current liabilities
24,396

 
24,881

Noncurrent liabilities
41,245

 
78,666

JV's partners' capital, net
51,672

 
62,543

Total liabilities and partners' capital, net
$
117,313

 
$
166,090

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
Net sales
$
953

 
$
540

 
$
1,611

 
$
540

Net loss
$
(11,435
)
 
$
(10,992
)
 
$
(34,610
)
 
$
(23,822
)